IFPMA-JPMA Collaboration on Global Health | Symposium jointly hosted by the International Federation of Pharmaceutical Manufacturers and | Associations (IFPMA) andthe Japan Pharmaceutical Manufacturers Association (JPMA) | Proposals for the G7 | Hiroshima Summit Health Agenda Applying lessons learned from COVID-19 and driving progress towards SDG3: a roadmap for action

Event Outline and Program

Event Outline

COVID-19 has challenged the international community to turn lessons learned into strategic commitments to build on what has worked well in the innovation response and what needs to be further improved. The pandemic also reinforced the importance of achieving the SDGs, and in particular, good health and well-being.

In 2023, the Japanese government will host the G7 Summit for the first time since Japan announced its international leadership in achieving universal health coverage (UHC) at the 2016 G7 Ise-Shima Summit. As Japan presides over the G7 Summit in 2023, the midway year for the implementation of the SDGs, there are high expectations for progress in the discussion of the health agenda.

In this symposium, we will invite leaders in health care policy and system building from Japan and the international community to discuss the challenges and solutions for global health in the post-COVID-19 era.

Registration page

Title	IFPMA-JPMA Collaboration on Global Health Symposium jointly hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the Japan Pharmaceutical Manufacturers Association (JPMA) Proposals for the G7 Hiroshima Summit Health Agenda Applying lessons learned from COVID-19 and driving progress towards SDG3: a roadmap for action
Date & Time	4:30 - 6:30 pm (JST), May 12, 2023 (Fri.)
Format	Held in hybrid format with Zoom webinar
Venue	Iino Hall & Conference Center, Room A (4F Iino Building) 2-1-1 Uchisaiwaicho, Chiyoda Ward, Tokyo
Hosted by:	International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Japan Pharmaceutical Manufacturers Association (JPMA)
Capacity	On-site participation: 50 pers./Online participation 400 pers. (first-come-first-served basis)
Admission	Free
Language	Japanese, English (Japanese-English simultaneous interpretation provided.)
Secretariat	IFPMA- JPMA Symposium Secretariat (International Department, Oscar Japan Co., Ltd.) e-mail: jpma-ifpma2023@oscar-japan.com

◆ Proposals from the pharmaceutical industry for the G7 Hiroshima Summit Health Agenda PDF

Program

Facilitator: Haruka Sakamoto, Senior Manager, Health and Global Policy Institute (HGPI)

16:30 – 16:35	Opening Remarks ● Yasushi Okada, President, Japan Pharmaceutical Manufacturers Association
16:35 – 16:55	Keynotes The roles and responsibilities of G7, and expectations for innovative pharmaceutical companies for "more resilient, equitable, and sustainable health systems" and "sustainable investment in innovation" ● Keizo Takemi, Member of the House of Councilors, Chairman of the LDP Special Committee on International Health Strategy ● Yasuhiro Suzuki, Executive Board Member, WHO; President, International University of Health and Welfare; former Chief Medical & Global Health Officer and Vice-Minister for Health, MHLW
16:55 – 17:55	Panel Discussion Lessons learned from COVID-19, preparedness and response to the next pandemic ● Keizo Takemi, Member of the House of Councilors, Chairman of the LDP Special Committee on International Health Strategy ● Osamu Kunii, CEO, Global Health Innovative Technology Fund (GHIT Fund) Deputy Director, Hiroshima G7 Global Health Task Force ● Heulwen Philpot, Head of Secretariat, IPPS (International Pandemic Preparedness Secretariat) ● Thomas Cueni, Director General, IFPMA (International Federation of Pharmaceutical Manufacturers and Associations)
17:55 - 18:25	Q&A Session
18:25 – 18:30	Closing Remarks ● Thomas Cueni, Director General, IFPMA (International Federation of Pharmaceutical Manufacturers and Associations)